Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Same-week appointments are often available
This medication was FDA-approved for weight loss in 2023, and studies have shown that participants lost an average of 35.5 pounds after 72 weeks of taking the medication at its lowest dose, with the average amount of weight loss getting higher as the dosage increases
The components of MIC/B-12 injections, particularly Methionine, Inositol, and Choline, are believed to support liver health
Proteins must be properly folded have the right shape to function properly in a cell